A Retrospective Claims Data Analysis on the Burden of COVID-19-Related Hospitalization in Adults at High Risk for Severe Disease Progression in Germany DOI Creative Commons

T Stremel,

S Schnaidt,

Nicole Bihrer

и другие.

Infectious Diseases and Therapy, Год журнала: 2024, Номер unknown

Опубликована: Дек. 8, 2024

Individuals at increased risk of severe coronavirus disease 2019 (COVID-19) progression have a higher probability being hospitalized. Nirmatrelvir/ritonavir (NMV/r) is an antiviral drug aiming to prevent courses. Our study aimed assess the resource utilization and costs adults hospitalized for COVID-19 high progression. A retrospective was conducted using German claims data. The presence high-risk criteria determined through recorded diagnoses, operations, procedures, prescriptions. progression, primarily COVID-19, required diagnosis additionally sepsis, pulmonary embolism, acute respiratory failure, pneumonia, or remdesivir prescription. Patients were grouped by eligibility NMV/r treatment (eligible, eligible with restrictions, not eligible). outcomes interest reported timeframe last dominant virus variant available in database, i.e., Delta (June 21, 2021 December 31, 2021). Of approximately 3.7 million individuals continuously observable about 60% identified as Among individuals, 2938 patients between June 2021, two-thirds which suitable (half without restrictions). Advanced age (86.3%) cardiovascular conditions (83.9%) most prevalent predefined factors. Identified stayed, on average, 11.3 days hospital, inpatient mortality 18.9%. These COVID-19-related hospitalizations resulted mean healthcare €8728. This reflects economic burden adult from payer's perspective Germany. findings highlight need courses associated relieve systems regarding allocation.

Язык: Английский

SARS-CoV-2 JN.1 variant evasion of IGHV3-53/3-66 B cell germlines DOI Open Access
Ida Paciello, Giuseppe Maccari, Giulio Pierleoni

и другие.

Science Immunology, Год журнала: 2024, Номер 9(98)

Опубликована: Авг. 9, 2024

The severe acute respiratory syndrome coronavirus 2 variant JN.1 recently emerged as the dominant despite having only one amino acid change on spike (S) protein receptor binding domain (RBD) compared with ancestral BA.2.86, which never represented more than 5% of global variants. To define at molecular level ability to spread globally, we interrogated a panel 899 neutralizing human monoclonal antibodies. Our data show that single leucine-455-to-serine mutation in RBD unleashed JN.1, likely occurring by elimination 70% antibodies mediated IGHV3-53/3-66 germlines. However, resilience class 3 low neutralization potency but strong Fc functions may explain absence disease.

Язык: Английский

Процитировано

8
From Detection to Protection: Antibodies and Their Crucial Role in Diagnosing and Combatting SARS-CoV-2 DOI Creative Commons
Anoop Kumar, Prajna Tripathi, Prashant Kumar

и другие.

Vaccines, Год журнала: 2024, Номер 12(5), С. 459 - 459

Опубликована: Апрель 25, 2024

Understanding the antibody response to SARS-CoV-2, virus responsible for COVID-19, is crucial comprehending disease progression and significance of vaccine therapeutic development. The emergence highly contagious variants poses a significant challenge humoral immunity, underscoring necessity grasping intricacies specific antibodies. This review emphasizes pivotal role antibodies in shaping immune responses their implications diagnosing, preventing, treating SARS-CoV-2 infection. It delves into kinetics characteristics explores current antibody-based diagnostics, discussing strengths, clinical utility, limitations. Furthermore, we underscore potential SARS-CoV-2-specific antibodies, various therapies such as monoclonal polyclonal anti-cytokines, convalescent plasma, hyperimmunoglobulin-based therapies. Moreover, offer insights vaccines, emphasizing neutralizing order confer immunity along with emerging concern (VOCs) circulating Omicron subvariants. We also highlight challenges field, risks antibody-dependent enhancement (ADE) shed light on associated original antigenic sin (OAS) effect long COVID. Overall, this intends provide valuable insights, which are advancing sensitive diagnostic tools, identifying efficient therapeutics, developing effective vaccines combat evolving threat global scale.

Язык: Английский

Процитировано

5
Population immunity enhances the evolution of SARS-CoV-2 in Beijing revealed by wastewater genomic surveillance DOI

Chen Wang,

Wenxiu Chen, Lina Yu

и другие.

Water Research, Год журнала: 2025, Номер 282, С. 123649 - 123649

Опубликована: Апрель 14, 2025

Язык: Английский

Процитировано

0
Computational Modeling of the Scenario of Resumption of Covid-19 Waves under Pulse Evolution in New Omicron Lines DOI
A. Yu. Perevaryukha

Technical Physics Letters, Год журнала: 2024, Номер unknown

Опубликована: Июль 10, 2024

Язык: Английский

Процитировано

2
Structural Basis for Evasion of New SARS-CoV-2 Variants from the Potent Virus-Neutralizing Nanobody Targeting the S-Protein Receptor-Binding Domain DOI Creative Commons
Nikolai N. Sluchanko, Dmitry V. Shcheblyakov, Larisa A. Varfolomeeva

и другие.

Biochemistry (Moscow), Год журнала: 2024, Номер 89(7), С. 1260 - 1272

Опубликована: Июль 1, 2024

Abstract COVID-19 has caused millions of deaths and many times more infections worldwide, emphasizing the unpreparedness global health system in face new key role for vaccines therapeutics, including virus-neutralizing antibodies, prevention containment disease. Continuous evolution SARS-CoV-2 coronavirus been causing its variants to evade action immune system, which highlighted importance detailed knowledge epitopes already selected potent antibodies. A single-chain antibody (“nanobody”) targeting receptor-binding domain (RBD), clone P2C5, had exhibited robust activity against all and, being a major component anti-COVID-19 formulation “GamCoviMab”, successfully passed Phase I clinical trials. However, after emergence Delta XBB variants, decrease neutralizing this nanobody was observed. Here we report on successful crystal structure determination RBD:P2C5 complex at 3.1 Å, revealed intricate protein–protein interface, sterically occluding full ACE2 receptor binding by P2C5-neutralized RBD. Moreover, developed interface centered around residues Leu452 Phe490, thereby explaining evasion or Omicron XBB, but not B.1.1.529 variant, as result single L452R F490S mutations, respectively, from P2C5. The obtained is expected foster engineering order rescue neutralization will facilitate epitope mapping other nanobodies competition assays.

Язык: Английский

Процитировано

0
Concerted deletions eliminate a neutralizing supersite in SARS-CoV-2 BA.2.87.1 spike DOI Creative Commons
Helen M. E. Duyvesteyn, Aiste Dijokaite-Guraliuc, Chang Liu

и другие.

Structure, Год журнала: 2024, Номер 32(10), С. 1594 - 1602.e6

Опубликована: Авг. 22, 2024

Summary

BA.2.87.1 represents a major shift in the BA.2 lineage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and is unusual having two lengthy deletions polypeptide spike (S) protein, one which removes beta-strand. Here we investigate its neutralization by variety sera from infected vaccinated individuals determine ectodomain structure. The receptor binding domain (RBD) structurally conserved RBDs are tightly packed an "all-down" conformation with small rotation relative to trimer axis as compared closest previously observed conformation. N-terminal (NTD) maintains remarkably similar structure overall; however, rearrangements resulting essentially destroy so-called supersite epitope eliminate glycan site, while mutation creates additional effectively shielding another NTD epitope. relatively easily neutralized but acquisition mutations RBD could increase antibody escape allowing it become dominant sub-lineage.

Язык: Английский

Процитировано

0
A Retrospective Claims Data Analysis on the Burden of COVID-19-Related Hospitalization in Adults at High Risk for Severe Disease Progression in Germany DOI Creative Commons

T Stremel,

S Schnaidt,

Nicole Bihrer

и другие.

Infectious Diseases and Therapy, Год журнала: 2024, Номер unknown

Опубликована: Дек. 8, 2024

Individuals at increased risk of severe coronavirus disease 2019 (COVID-19) progression have a higher probability being hospitalized. Nirmatrelvir/ritonavir (NMV/r) is an antiviral drug aiming to prevent courses. Our study aimed assess the resource utilization and costs adults hospitalized for COVID-19 high progression. A retrospective was conducted using German claims data. The presence high-risk criteria determined through recorded diagnoses, operations, procedures, prescriptions. progression, primarily COVID-19, required diagnosis additionally sepsis, pulmonary embolism, acute respiratory failure, pneumonia, or remdesivir prescription. Patients were grouped by eligibility NMV/r treatment (eligible, eligible with restrictions, not eligible). outcomes interest reported timeframe last dominant virus variant available in database, i.e., Delta (June 21, 2021 December 31, 2021). Of approximately 3.7 million individuals continuously observable about 60% identified as Among individuals, 2938 patients between June 2021, two-thirds which suitable (half without restrictions). Advanced age (86.3%) cardiovascular conditions (83.9%) most prevalent predefined factors. Identified stayed, on average, 11.3 days hospital, inpatient mortality 18.9%. These COVID-19-related hospitalizations resulted mean healthcare €8728. This reflects economic burden adult from payer's perspective Germany. findings highlight need courses associated relieve systems regarding allocation.

Язык: Английский

Процитировано

0